Futures in Biotech 71
Recorded: November 19, 2010
Published: November 22, 2010
Futures in Biotech 71: Genomics, Proteomics, Cellular Immunity, and Anti-Matter
The '1000 Genome Project', 'Billion Dollar Human Proteome', viral killing proteins, and capturing anti-matter.
- Vincent Racaniello, PhD, TWiT.TV
- Professor of Microbiology & Host of This Week in Virology, Host of This Week in Parasitism, Columbia University, New York, NY
- Andre Nantel PhD, Senior Research Officer, BRI Microarray Lab, National Research Council of Canada, Montreal QC
- Dr. George Farr, VP Aeromics, LLC
- Mark Gerstein, Yale University, Albert L Williams Professor of Biomedical Informatics, Molecular Biophysics & Biochemistry, and Computer Science
Journal Club format PNAS paper: TRIM 21, a ubiquitin ligase, has an Ab binding domain; virus neutralization may work by Ab binds V, complex is degraded in proteasome.
Nature paper: 1000 genomes project. First genomes from two males of European descent. Sequence e.g. parents and child. Discuss SNPs, indels, lethal haplotypes. Retroviral proportion of genome.
Human proteome project: first tricorder run. Fingerprint of all cell types. Goal 1: protein encyclopaedia - each gene product. Goal 2. Tissue distribution and subcellular localization. Goal 3. Protein pathway - network map - of proteome. "The mass spectrometer is ready to go." Discussion of logistics, feasibility.
- Synergy 1
- ad times: :27- :50 and 22:32 - 26:00
- Edited by: Jeff
|This area is for use by TWiT staff only. Please do not add or edit any content within this section.|